Sangamo BioSciences Inc. (NASDAQ:SGMO) was up 1.3% on Friday . The stock traded as high as $5.74 and last traded at $5.66, with a volume of 273,702 shares trading hands. The stock had previously closed at $5.59.

Several equities research analysts recently weighed in on SGMO shares. Wells Fargo & Co. started coverage on Sangamo BioSciences in a research report on Tuesday, May 3rd. They set a “buy” rating on the stock. Wedbush reissued an “outperform” rating and issued a $30.00 target price on shares of Sangamo BioSciences in a report on Friday, May 6th. Jefferies Group reissued a “buy” rating and issued a $14.00 target price on shares of Sangamo BioSciences in a report on Thursday, June 9th. Finally, Zacks Investment Research downgraded Sangamo BioSciences from a “hold” rating to a “sell” rating in a report on Tuesday, July 5th. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the stock. Sangamo BioSciences currently has a consensus rating of “Buy” and an average price target of $16.75.

The firm’s market capitalization is $403.21 million. The firm has a 50-day moving average of $6.16 and a 200-day moving average of $6.24.

Sangamo BioSciences (NASDAQ:SGMO) last issued its quarterly earnings results on Monday, May 2nd. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.01. The business earned $3.94 million during the quarter, compared to analysts’ expectations of $5.49 million. During the same quarter in the previous year, the company posted ($0.08) earnings per share. The company’s quarterly revenue was down 70.8% compared to the same quarter last year. On average, equities analysts expect that Sangamo BioSciences Inc. will post ($0.98) EPS for the current fiscal year.

An institutional investor recently raised its position in Sangamo BioSciences stock. California State Teachers Retirement System raised its stake in Sangamo BioSciences Inc. (NASDAQ:SGMO) by 1.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 128,941 shares of the biopharmaceutical company’s stock after buying an additional 2,257 shares during the period. California State Teachers Retirement System owned approximately 0.18% of Sangamo BioSciences worth $1,177,000 at the end of the most recent reporting period.

Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.